Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 6.54Hester Biosciences Ltd shows a mixed financial performance. The company demonstrates strong growth and profitability, reflected in high scores for growth and profitability ratios. Its solvency is also good, indicating a stable financial structure. However, there are areas of concern, particularly in efficiency and liquidity. The company's efficiency ratios suggest challenges in asset utilization, while liquidity ratios indicate potential difficulties in meeting short-term obligations. The financial ratios also need improvement, reflecting lower earnings per share and higher capital expenditures. While the company shows robust growth and profitability, it needs to address its efficiency and liquidity to ensure long-term financial stability.
Health Score : 6.54Hester Biosciences Ltd shows a mixed financial performance. The company demonstrates strong growth and profitability, reflected in high scores for growth and profitability ratios. Its solvency is also good, indicating a stable financial structure. However, there are areas of concern, particularly in efficiency and liquidity. The company's efficiency ratios suggest challenges in asset utilization, while liquidity ratios indicate potential difficulties in meeting short-term obligations. The financial ratios also need improvement, reflecting lower earnings per share and higher capital expenditures. While the company shows robust growth and profitability, it needs to address its efficiency and liquidity to ensure long-term financial stability.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
35.93
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
33.64
P/B RATIO
5.20
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
5.55
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
18.29
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹2200.5 as on Sep 1, 2026.
Growth Score : 10.00The growth ratios reflect strong growth across key metrics. High revenue, operating profit, EPS, asset, and net income growth rates demonstrate the company's ability to expand its operations and increase profitability. Sustaining this growth trajectory will be crucial for long-term success and shareholder value creation. The company is performing well in terms of growth and is expected to perform well in future.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 9.81 | 13.19 | 14.66 | 1.97 | 7.07 |
| Operating Profit Growth Rate | -13.04 | -15 | 5.88 | 14.81 | 40.32 |
| Earnings Per Share (EPS) Growth | 14.21 | -32.28 | -29.04 | 45.48 | 102.45 |
| Asset Growth Rate | 36.74 | 19.22 | -1.19 | -1.36 | 3.83 |
| Net Income Growth Rate | 11.43 | -28.21 | -25 | 38.1 | 96.55 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 37.27 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 70.69 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 4 | Windlas Biotech Ltd | 7.52 | 32.03 | Neutral | 105.00 | 32.19 | 66.00 |
| 5 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.89 | Neutral | 98.00 | 43.88 | 88.00 |
| 6 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 7 | NGL Fine Chem Ltd | 6.98 | 34.11 | Neutral | 73.00 | 67.39 | 48.00 |
| 8 | Syncom Formulations (India) Ltd | 6.92 | 24.78 | Neutral | 77.00 | 0.81 | 76.00 |
| 9 | Sakar Healthcare Ltd | 6.89 | 70.49 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 10 | Kopran Ltd | 6.60 | 40.82 | Undervalued | 62.00 | 6.30 | 26.00 |
| 11 | Hester Biosciences Ltd | 6.54 | 33.64 | Neutral | 87.00 | 61.24 | 57.00 |
| 12 | Sigachi Industries Ltd | 6.49 | -14.82 | Neutral | 54.00 | -2.08 | -83.00 |
| 13 | Medicamen Biotech Ltd | 5.73 | 37.61 | Neutral | 20.00 | 6.94 | 10.00 |
| 14 | Remus Pharmaceuticals Ltd | 5.31 | 27.61 | Neutral | 57.00 | 20.97 | 46.00 |
| 15 | Ind-Swift Laboratories Ltd | 4.95 | 77.18 | Neutral | 45.00 | 4.89 | 41.00 |
| 16 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 17 | Wanbury Ltd | 4.65 | 27.30 | Neutral | 88.00 | 15.98 | 43.00 |
| 18 | Solara Active Pharma Sciences Ltd | 4.34 | -313.88 | Neutral | 187.00 | -1.50 | -7.00 |
| 19 | NOVARTIND | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
Concall Report⬤2nd Feb 26
Q3 and 9M FY26 Earnings Conference Call
NEUTRAL SENTIMENT
Concall Report⬤12th Nov 25
Q2/H1 FY26 Earnings Conference Call
NEUTRAL SENTIMENT
Hester Biosciences Ltd is an Indian animal health company, a prominent manufacturer of animal vaccines and health products. Specializing in poultry and large animal segments, it also has a growing presence in pet care and diagnostic services. The company is focused on expanding its domestic and international market footprint, particularly in Africa.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Hester Biosciences Ltd's P/E ratio (TTM) is 35.93, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Hester Biosciences Ltd's P/B ratio is 5.20, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Hester Biosciences Ltd's P/S ratio is 5.55, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Hester Biosciences Ltd's PEG ratio is N/A.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Hester Biosciences Ltd's EV/EBITDA ratio is 18.29.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Hester Biosciences Ltd's ROE is 15.79%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Hester Biosciences Ltd's ROA is 12.83%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Hester Biosciences Ltd's ROCE is 15%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Hester Biosciences Ltd's operating margin is 26.13%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Hester Biosciences Ltd's net margin is 17.12%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Hester Biosciences Ltd's current ratio is 0.97.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Hester Biosciences Ltd's debt-to-equity ratio is 0.27.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Hester Biosciences Ltd's interest coverage ratio is 7.91.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Hester Biosciences Ltd's DPS is ₹11.12.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Hester Biosciences Ltd's EPS is 102.45.
(Source line: "Ratios as of 09 Nov 2026, based on last traded price of ₹2200.50. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1987
Headquarters: Ahmedabad, Gujarat
Core Offerings: Poultry Vaccines, Animal Vaccines, Animal Health Products, Pet Care Products, Diagnostic Services
Stock Listing: NSE (HESTERBIO), BSE (524669)
Promoter: Rajiv Gandhi / Gandhi Family Group
Hester Biosciences was incorporated in 1987. Commercial production of animal vaccines commenced in 1997. The company expanded its product portfolio into large animal health products in 2008, followed by poultry health products in 2013. A significant step in its global expansion was the establishment of a wholly-owned subsidiary in Tanzania in 2018 to cater to the African market. In 2021, Hester Biosciences diversified into the pet care segment, further broadening its animal health offerings.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Animal Biologicals (Vaccines) | 54.7% (FY23) | Operating Profit |
| Animal Health Products | 39.8% (FY23) | Operating Profit |
| Other Operating Revenue (Trading & Services) | 5.5% (FY23) | Operating Profit |
Animal Biologicals (Vaccines): Manufactures and markets a comprehensive range of live and inactivated vaccines for poultry and large animals, addressing various diseases.
Animal Health Products: Offers therapeutic formulations, feed supplements, and other non-vaccine pharmaceutical products for livestock and poultry.
Pet Care: Provides specialized products including dietary supplements, dewormers, and dermatological solutions for companion animals.
Diagnostic Services: Operates an advanced diagnostic laboratory offering testing and analytical services for animal diseases.
Mr. Rajiv Gandhi - Managing Director & CEO. He is the founder of Hester Biosciences and has been instrumental in its growth, bringing over three decades of experience and vision to the animal healthcare industry.
Hester Biosciences Africa Limited (Tanzania)
Hester Biosciences Nepal Pvt. Ltd.
Hester Retail Private Limited
The company issued a Bonus Share in the ratio of 1:2 (1 equity share for every 2 held) in 2017. In 2021, Hester Biosciences completed a Rights Issue, raising capital for business expansion.
The Hester Biosciences Ltd share price today is ₹2200.50 on NSE (HESTERBIO), as of 10 Nov 2026.
As of 09 Nov 2026, Hester Biosciences Ltd share price is ₹2200.50, with previous close ₹2200.50. Today's range is ₹2200.50 to ₹2200.50. The 52-week range is ₹1239.30 to ₹2683.60.
As of today, Hester Biosciences Ltd's market cap is ₹1,848.42 crore (Small Cap).
Hester Biosciences Ltd's current P/E ratio is 35.93, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 36.
Hester Biosciences Ltd's current P/B ratio is 5.20.
Hester Biosciences Ltd's current dividend yield is 0.51%. Last dividend of ₹3.00 per share was declared on 30-May-2023.
Hester Biosciences Ltd's EPS (TTM) is ₹102.45.
Hester Biosciences Ltd is an Indian animal health company, a prominent manufacturer of animal vaccines and health products. Specializing in poultry and large animal segments, it also has a growing presence in pet care and diagnostic services. The company is focused on expanding its domestic and international market footprint, particularly in Africa.
Hester Biosciences Ltd is promoted by Rajiv Gandhi / Gandhi Family Group, holding 53.73% as of 09 Nov 2026.
Hester Biosciences Ltd is listed on NSE (HESTERBIO) and BSE (524669). Its next quarterly results are expected on August 2024.
Dividend Per Share (DPS)
